Cocrystal Pharma, Inc. (COCP) — Financial statements
Income statement, balance sheet, and cash flow for Cocrystal Pharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 13↓17.4% | 15↑22.4% | 12↑40.9% | 9 | |
| Gross Profit | 0.00↑100.0% | -13↑17.4% | -15↓22.4% | -12↓40.9% | -9 | |
| Operating Expenses | ||||||
| R&D Expenses | 5↓59.7% | 13↓17.4% | 15↑22.4% | 12↑40.9% | 9 | |
| General & Administrative Expenses | 4↓25.8% | 5↓10.8% | 6↑4.3% | 6↑5.9% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 4↓25.8% | 5↓10.8% | 6↑4.3% | 6↑5.9% | 5 | |
| Other Expenses | 0.00↑100.0% | -13↑29.4% | -18↓314.1% | 8↑194.4% | -9 | |
| Operating Expenses | 9↑68.9% | 5↑57.6% | 3↓87.2% | 26↑387.1% | 5 | |
| Total Costs & Expenses | 9↓49.6% | 18↓3.7% | 19↓52.2% | 39↑173.0% | 14 | |
| Operating Results | ||||||
| Operating Income | -9↑49.6% | -18↑3.7% | -19↑52.2% | -39↓173.0% | -14 | |
| Depreciation & Amortization | 0.38↑198.4% | 0.13↓33.3% | 0.19↑2.2% | 0.19↓2.6% | 0.19 | |
| EBITDA | -9↑51.3% | -18↑15.3% | -21↓16.8% | -18↓27.9% | -14 | |
| EBIT | -9↑49.6% | -18↑15.5% | -21↓16.7% | -18↓27.5% | -14 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 0.54↓16.1% | 0.64↑32132.0% | -0.00↑50.0% | -0.00 | |
| Interest Income | 0.00↓100.0% | 0.54↓16.1% | 0.64↑31999900.0% | 0.00↓50.0% | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.00↓50.0% | 0.00 | |
| Non-Operating Income | 0.00 | 0.00↓100.0% | 3↑112.6% | -21 | 0.00 | |
| Other Income / Expenses | 0.19↓49.7% | 0.37↓35.0% | 0.58↑7287.5% | -0.01↓122.2% | 0.04 | |
| Income Before Tax | -9↑49.5% | -18↑2.7% | -18↑53.7% | -39↓173.8% | -14 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -9↑49.5% | -18↑2.7% | -18↑53.7% | -39↓173.8% | -14 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -9↑49.5% | -18↑2.7% | -18↑53.7% | -39↓173.8% | -14 | |
| Bottom-Line Net Income | -9↑49.5% | -18↑2.7% | -18↑53.7% | -39↓173.8% | -14 | |
| EPS (Basic) | -0.78↑54.7% | -1.72↓90426.3% | -0.00↑100.0% | -4.77↓157.8% | -1.85 | |
| EPS (Diluted) | -0.78↑54.7% | -1.72↓90426.3% | -0.00↑100.0% | -4.77↓157.8% | -1.85 | |
| Weighted Average Shares | 11↑11.0% | 10↑5.4% | 10↑18.5% | 8↑5.9% | 8 | |
| Weighted Average Diluted Shares | 11↑11.0% | 10↑5.4% | 10↑18.5% | 8↑5.9% | 8 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.